-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 23, CDE's official website showed that Eli Lilly's new indication for Ramoxiuximab was declared for marketing (acceptance number: JXSS2101017)
Ramoxicamab is a human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit the activation of VEGFR-2, thereby inhibiting ligand-induced endothelial cell proliferation and migration.
The Insight database shows that ramucirumab was first approved by the FDA for marketing on November 5, 2014, under the trade name CYRAMZA
The Insight database shows that ramucirumab was first approved by the FDA for marketing on November 5, 2014, under the trade name CYRAMZA
From the Insight database (http://db.
Since its approval to go public, its sales have continued to grow, and the Insight database shows that its sales have exceeded 1 billion yuan in 2020
Since its approval to go public, its sales have continued to grow, and the Insight database shows that its sales have exceeded 1 billion yuan in 2020
From the Insight database (http://db.
In China, Eli Lilly submitted a clinical application for this product as early as 2010
Two are phase 3 clinical , respectively are second-line gastric cancer and second-line hepatocellular carcinoma
Timeline of Remoluzumab Project
The status of the clinical trials of ramucirumab in China
From the Insight database (http://db.
However, Eli Lilly's original research product has not yet been launched, and domestic biosimilar drug companies are already eager to try
Ramucirumab biosimilars that have entered phase I clinical trials in China ( click here for details )
Click here for details
From the Insight database (http://db.
